<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04424914</url>
  </required_header>
  <id_info>
    <org_study_id>B3461087</org_study_id>
    <secondary_id>ATRIS</secondary_id>
    <secondary_id>HFpEF ATTR-CM prevalence study</secondary_id>
    <secondary_id>2020-002378-29</secondary_id>
    <nct_id>NCT04424914</nct_id>
  </id_info>
  <brief_title>Global Prevalence of ATTR-CM in Participants With HFpEF</brief_title>
  <official_title>GLOBAL PREVALENCE OF TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) IN PARTICIPANTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFpEF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a global, multi-center study designed to estimate the global prevalence of
      transthyretin amyloid cardiomyopathy (ATTR-CM) within a clinically at risk population
      [participants with heart failure with preserved ejection fraction (HFpEF)].
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 16, 2020</start_date>
  <completion_date type="Anticipated">January 12, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 28, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>To determine global prevalence of transthyretin amyloid cardiomyopathy in participants diagnosed with heart failure with preserved ejection fraction. No study treatment will be dispensed however, participants will undergo scintigraphy and if result is grade 1, will undergo a confirmatory endomyocardial biopsy.</intervention_model_description>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimate of global prevalence of ATTR-CM in HFpEF patients.</measure>
    <time_frame>Visit 1(baseline) through Follow-Up Visit 1 (Day 44)</time_frame>
    <description>Includes participants not previously diagnosed with ATTR-CM but found to be positive by scintigraphy at Visit 1 (or subsequent biopsy at Visit 2 if required).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimate of prevalence of ATTR-CM within region, age and gender</measure>
    <time_frame>Visit 1(baseline) through Follow-Up Visit 1 (Day 44)</time_frame>
    <description>Includes participants not previously diagnosed with ATTR-CM but found to be positive by scintigraphy at Visit 1 (or subsequent biopsy at Visit 2 if required).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of patients diagnosed ATTR-CM on study with WT and hereditary forms among patients diagnosed with ATTR CM</measure>
    <time_frame>Visit 1(baseline) through Follow-Up Visit 1 (Day 44)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) Classification of HFpEF participants diagnosed with ATTR-CM compared with HFpEF participants negative for ATTR-CM</measure>
    <time_frame>Visit 1(baseline) through Follow-Up Visit 1 (Day 44)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-Minute Walk Test results of HFpEF participants diagnosed with ATTR-CM compared with HFpEF participants negative for ATTR-CM</measure>
    <time_frame>Visit 1(baseline) through Follow-Up Visit 1 (Day 44)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nt-proBNP results of HFpEF participants diagnosed with ATTR-CM compared with HFpEF participants negative for ATTR-CM</measure>
    <time_frame>Visit 1(baseline) through Follow-Up Visit 1 (Day 44)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Transthyretin Amyloid Cardiomyopathy</condition>
  <condition>Heart Failure With Preserved Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>ATTR-CM positive</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants diagnosed with ATTR-CM by scintigraphy (and confirmatory biopsy if required).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATTR-CM negative</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants who are scintigraphy negative for ATTR-CM</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Scintigraphy</intervention_name>
    <description>scintigraphy and confirmatory endomyocardial biopsy if needed</description>
    <arm_group_label>ATTR-CM negative</arm_group_label>
    <arm_group_label>ATTR-CM positive</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Medical history of heart failure (HF) with:

               1. At least 1 episode with clinical evidence of HF (without hospitalization) by
                  signs or symptoms of volume overload or elevated intracardiac pressures that
                  required/requires treatment with a diuretic for improvement; OR

               2. 1 prior hospitalization for HF.

          2. Left ventricular ejection fraction (LVEF) &gt;40%.

          3. End-diastolic interventricular septal wall thickness (IVST) ≥12 mm.

          4. Willing and able to undergo scintigraphy and biopsy (if Grade 1 scintigraphy).

          5. NT-ProBNP ≥600 pg/ml.

        Exclusion Criteria:

          1. Diagnosis of heart failure with reduced ejection fraction (HFrEF) (EF ≤40%).

          2. Presence or history of ischemic heart disease affecting at least 1 of the main
             coronary arteries.

          3. Presence or history of any severe valvular heart disease (obstructive or regurgitant).

          4. A confirmed diagnosis of a non-amyloid infiltrative cardiomyopathy (ie, cardiac
             sarcoidosis, hemochromatosis), muscular dystrophies, cardiomyopathy with reversible
             causes, hypertrophic obstructive cardiomyopathy with known genetic etiology, or known
             pericardial constriction.

          5. Any type of diagnosed amyloidosis (eg, amyloid A amyloidosis, primary [light chain]
             amyloidosis) or prior diagnosis of ATTR-CM.

             -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B3461087</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 27, 2020</study_first_submitted>
  <study_first_submitted_qc>June 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>June 5, 2020</last_update_submitted>
  <last_update_submitted_qc>June 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prevalence</keyword>
  <keyword>transthyretin amyloid</keyword>
  <keyword>ATTR-CM</keyword>
  <keyword>HFpEF</keyword>
  <keyword>scintigraphy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

